Fig. 4: This figure shows the impact of early response on survival stratified by baseline disease (Mayo) stage showing an improvement in outcomes with deeper responses across all stages.
From: Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
A Kaplan–Meier curve showing overall survival of Mayo stage 1 patients, stratified by their haematologic response at 1 month (≥ VGPR vs < VGPR). The median OS of patients with ≥ VGPR was not reached when compared to 88 months (95% CI 72.65–103.35 months) in patients with < VGPR (P < 0.005). B Kaplan–Meier curve showing overall survival of Mayo stage 2 patients, stratified by their haematologic response at 1 month (≥ VGPR vs < VGPR). The median OS of patients with ≥ VGPR was not reached when compared to 58 months (95% CI 41–74.99 months) in patients with < VGPR (P < .005). C Kaplan–Meier curve showing overall survival of Mayo stage 3 patients, stratified by their haematologic response at 1 month (≥ VGPR vs < VGPR). The median OS of patients with ≥ VGPR was median 74 months when compared to 30 months (95% CI 23.69–36.30 months) in patients with < VGPR (P < 0.005). D Kaplan–Meier curve showing overall survival of Mayo stage 3B patients, stratified by their haematologic response at 1 month (≥ VGPR vs < VGPR). The median OS of patients with ≥ VGPR was 31 months (95% CI 11.05–50.95 months) when compared to 7 months (95% CI 3.03–10.96 months) in patients with < VGPR (P < 0.005).
